Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate With or Without Adalimumab in Early Arthritis
NCT00291915Phase 4Unknown
- Sponsor
- GERC
- Start
- May 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by GERC. Primary endpoint: Disease Activity Score at 12 months. Status: unknown.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00291915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291915.